Showing 123 results
-
Media Release /In observance of Cholesterol Education Month this September, Novartis associates across Asia-Pacific, Middle East & Africa (APMA) Region are getting their cholesterol tested and engaging key…
-
Media Release /Key stakeholders expressed their commitment to work together in addressing barriers to breast cancer care in the country during the final roundtable of the “Inspiring Conversations on Breast Cancer…
-
Media Release /Leadership and unified multisectoral efforts are needed to move cancer control in the Philippines forward. This was the key message of public and private sector speakers during the fourth “Inspiring…
-
Media Release /For cancer control programs in the country to be effective and sustainable, public-private partnerships are a must. This was the consensus formed by participants of the third “Inspiring Conversations…
-
Media Release /Novartis Healthcare Philippines is holding a series of activities dubbed “Project ASP: Ayoko Sa Plastic” (I Don’t Like Plastic) to help reduce plastic footprint and promote awareness on responsible…
-
Media Release /A nationwide breast cancer screening program, multistakeholder collaboration, innovation, and patient-centricity are key factors in enhancing breast cancer care in the country. These were the main…
-
Media Release /The first of a series of roundtable discussions aiming to promote awareness on breast cancer and help address gaps in breast cancer care kicked off today with key stakeholders from the public and…
-
Media Release /In 2022, Novartis contributed PHP 7.5 billion to the Gross Domestic Product (GDP). Nineteen percent (19%) of our total GDP contribution in the Philippines stems from innovation (R&D) The full…
-
Media Release /Media plays an important role in promoting public awareness on good health practices and disease prevention. Recognizing the key role of media in health literacy promotion, Novartis Healthcare…
-
Media Release /RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i)…
